NCT04583501View on ClinicalTrials.gov

Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

July 12, 2024

Study Completion Date

July 12, 2024

Conditions
Chronic Rhinosinusitis With Nasal PolypsNasal Polyps
Interventions
BIOLOGICAL

Omalizumab

Omalizumab will used as dose comparable to to 0.016 mg/kg/IU in serum.

Trial Locations (2)

21117

Johns Hopkins Bayview Medical Center, Baltimore

21287

Johns Hopkins Hospital, Baltimore

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Johns Hopkins University

OTHER

NCT04583501 - Preclinical Studies of Omalizumab in Chronic Rhinosinusitis With Nasal Polyposis | Biotech Hunter | Biotech Hunter